Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions

R. P. Perng, Y. M. Chen, M. F. Wu, K. C. Chou, W. C. Lin, J. M. Liu, J. Whang-Peng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

A phase II clinical trial of intrapleural paclitaxel injection for malignant effusions of non-small-cell lung cancer (NSCLC) was conducted in order to evaluate the efficacy and toxicity profile of paclitaxel pleurodesis in patients with malignant effusions. From February to May of 1996, 15 NSCLC patients with malignant pleural effusions were enrolled on study. After adequate drainage and assurance of lung re-expansion, paclitaxel 125 mg m-2 diluted in normal saline was infused through a preinserted pig-tail catheter which was removed 2 h later. Chest radiography and sonography were scheduled 4 days later; depending on whether there remained a significant amount of pleural effusion, further drainage by needle thoracentesis or by a pig-tail catheter was performed. All patients were assessable for toxicity. Ipsilateral chest and/or shoulder pain, fever, facial flushing and nausea were the most frequent side-effects. Grade 4 neutropenia, grade 3 anaemia, and grade 3 renal impairment occurred in one patient each. Fourteen patients were evaluable for response at the end of the fourth week. Overall response rate of pleural effusion in evaluable patients was 92.9%, with a complete response rate of 28.6%. There was one out of 14 evaluable patients whose measurable tumour lesion decreased by more than 50% (partial response). No disease progression was noted among evaluable patients at the end of the fourth week. It is concluded that paclitaxel is a useful agent for the treatment of malignant pleural effusions. Because of its relatively low systemic toxicity, intrapleural paclitaxel injection in combination with systemic chemotherapy or radiotherapy can be considered in treating NSCLC patients with malignant pleural effusions.

Original languageEnglish
Pages (from-to)473-479
Number of pages7
JournalRespiratory Medicine
Volume92
Issue number3
DOIs
Publication statusPublished - Jan 1 1998
Externally publishedYes

Fingerprint

Malignant Pleural Effusion
Paclitaxel
Non-Small Cell Lung Carcinoma
Injections
Pleural Effusion
Tail
Drainage
Swine
Catheters
Pleurodesis
Phase II Clinical Trials
Shoulder Pain
Neutropenia
Chest Pain
Radiography
Nausea
Needles
Disease Progression
Anemia
Ultrasonography

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. / Perng, R. P.; Chen, Y. M.; Wu, M. F.; Chou, K. C.; Lin, W. C.; Liu, J. M.; Whang-Peng, J.

In: Respiratory Medicine, Vol. 92, No. 3, 01.01.1998, p. 473-479.

Research output: Contribution to journalArticle

Perng, R. P. ; Chen, Y. M. ; Wu, M. F. ; Chou, K. C. ; Lin, W. C. ; Liu, J. M. ; Whang-Peng, J. / Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. In: Respiratory Medicine. 1998 ; Vol. 92, No. 3. pp. 473-479.
@article{1cbd2b919b3e4ba7b52ecaa308e8ca33,
title = "Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions",
abstract = "A phase II clinical trial of intrapleural paclitaxel injection for malignant effusions of non-small-cell lung cancer (NSCLC) was conducted in order to evaluate the efficacy and toxicity profile of paclitaxel pleurodesis in patients with malignant effusions. From February to May of 1996, 15 NSCLC patients with malignant pleural effusions were enrolled on study. After adequate drainage and assurance of lung re-expansion, paclitaxel 125 mg m-2 diluted in normal saline was infused through a preinserted pig-tail catheter which was removed 2 h later. Chest radiography and sonography were scheduled 4 days later; depending on whether there remained a significant amount of pleural effusion, further drainage by needle thoracentesis or by a pig-tail catheter was performed. All patients were assessable for toxicity. Ipsilateral chest and/or shoulder pain, fever, facial flushing and nausea were the most frequent side-effects. Grade 4 neutropenia, grade 3 anaemia, and grade 3 renal impairment occurred in one patient each. Fourteen patients were evaluable for response at the end of the fourth week. Overall response rate of pleural effusion in evaluable patients was 92.9{\%}, with a complete response rate of 28.6{\%}. There was one out of 14 evaluable patients whose measurable tumour lesion decreased by more than 50{\%} (partial response). No disease progression was noted among evaluable patients at the end of the fourth week. It is concluded that paclitaxel is a useful agent for the treatment of malignant pleural effusions. Because of its relatively low systemic toxicity, intrapleural paclitaxel injection in combination with systemic chemotherapy or radiotherapy can be considered in treating NSCLC patients with malignant pleural effusions.",
author = "Perng, {R. P.} and Chen, {Y. M.} and Wu, {M. F.} and Chou, {K. C.} and Lin, {W. C.} and Liu, {J. M.} and J. Whang-Peng",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0954-6111(98)90294-3",
language = "English",
volume = "92",
pages = "473--479",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions

AU - Perng, R. P.

AU - Chen, Y. M.

AU - Wu, M. F.

AU - Chou, K. C.

AU - Lin, W. C.

AU - Liu, J. M.

AU - Whang-Peng, J.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - A phase II clinical trial of intrapleural paclitaxel injection for malignant effusions of non-small-cell lung cancer (NSCLC) was conducted in order to evaluate the efficacy and toxicity profile of paclitaxel pleurodesis in patients with malignant effusions. From February to May of 1996, 15 NSCLC patients with malignant pleural effusions were enrolled on study. After adequate drainage and assurance of lung re-expansion, paclitaxel 125 mg m-2 diluted in normal saline was infused through a preinserted pig-tail catheter which was removed 2 h later. Chest radiography and sonography were scheduled 4 days later; depending on whether there remained a significant amount of pleural effusion, further drainage by needle thoracentesis or by a pig-tail catheter was performed. All patients were assessable for toxicity. Ipsilateral chest and/or shoulder pain, fever, facial flushing and nausea were the most frequent side-effects. Grade 4 neutropenia, grade 3 anaemia, and grade 3 renal impairment occurred in one patient each. Fourteen patients were evaluable for response at the end of the fourth week. Overall response rate of pleural effusion in evaluable patients was 92.9%, with a complete response rate of 28.6%. There was one out of 14 evaluable patients whose measurable tumour lesion decreased by more than 50% (partial response). No disease progression was noted among evaluable patients at the end of the fourth week. It is concluded that paclitaxel is a useful agent for the treatment of malignant pleural effusions. Because of its relatively low systemic toxicity, intrapleural paclitaxel injection in combination with systemic chemotherapy or radiotherapy can be considered in treating NSCLC patients with malignant pleural effusions.

AB - A phase II clinical trial of intrapleural paclitaxel injection for malignant effusions of non-small-cell lung cancer (NSCLC) was conducted in order to evaluate the efficacy and toxicity profile of paclitaxel pleurodesis in patients with malignant effusions. From February to May of 1996, 15 NSCLC patients with malignant pleural effusions were enrolled on study. After adequate drainage and assurance of lung re-expansion, paclitaxel 125 mg m-2 diluted in normal saline was infused through a preinserted pig-tail catheter which was removed 2 h later. Chest radiography and sonography were scheduled 4 days later; depending on whether there remained a significant amount of pleural effusion, further drainage by needle thoracentesis or by a pig-tail catheter was performed. All patients were assessable for toxicity. Ipsilateral chest and/or shoulder pain, fever, facial flushing and nausea were the most frequent side-effects. Grade 4 neutropenia, grade 3 anaemia, and grade 3 renal impairment occurred in one patient each. Fourteen patients were evaluable for response at the end of the fourth week. Overall response rate of pleural effusion in evaluable patients was 92.9%, with a complete response rate of 28.6%. There was one out of 14 evaluable patients whose measurable tumour lesion decreased by more than 50% (partial response). No disease progression was noted among evaluable patients at the end of the fourth week. It is concluded that paclitaxel is a useful agent for the treatment of malignant pleural effusions. Because of its relatively low systemic toxicity, intrapleural paclitaxel injection in combination with systemic chemotherapy or radiotherapy can be considered in treating NSCLC patients with malignant pleural effusions.

UR - http://www.scopus.com/inward/record.url?scp=0031954991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031954991&partnerID=8YFLogxK

U2 - 10.1016/S0954-6111(98)90294-3

DO - 10.1016/S0954-6111(98)90294-3

M3 - Article

C2 - 9692108

AN - SCOPUS:0031954991

VL - 92

SP - 473

EP - 479

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 3

ER -